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Abstract
Background: There is no reliable biomarker for predicting the prognosis of patients who undergo radical
cystectomy for bladder cancer. Recent studies have shown that the neutrophil-to-lymphocyte ratio (NLR) could
function as a useful prognostic factor in several types of malignancies. This study aimed to assess the usefulness of
NLR in bladder cancer.
Methods: A total of 74 patients who underwent radical cystectomy in our institutions from 1999 to 2014 were
analyzed. The NLR was calculated using the patients’ neutrophil and lymphocyte counts before radical cystectomy.
An immunohistochemical analysis was also performed to detect tumor infiltrating neutrophils (CD66b) and
lymphocytes (CD8) in bladder cancer specimens.
Results: A univariate analysis showed that the patients with a high NLR (≥2.38; HR = 4.84; p = 0.007), high C-reactive
protein level (>0.08; HR = 10.06; p = 0.030), or pathological lymph node metastasis (HR = 4.73; p = 0.030) had a
significantly higher risk of cancer-specific mortality. Kaplan-Meier and log-rank tests further revealed that NLR was
strongly correlated with overall survival (p = 0.018), but not progression-free survival (p = 0.137). In a multivariate
analysis, all of these were found to be independent risk factors (HR = 4.62, 10.8, and 12.35, respectively). The number
of CD8-positive lymphocytes was significantly increased in high-grade (p = 0.001) and muscle-invasive (p = 0.012)
tumors, in comparison to low-grade and non-muscle-invasive tumors, respectively.
Conclusions: The NLR predicted the prognosis of patients who underwent radical cystectomy and might therefore
function as a reliable biomarker in cases of invasive bladder cancer.
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Background
Urinary bladder cancer is one of the most commonly di-
agnosed malignancies [1]. Two-thirds to three-fourths of
patients with bladder tumor initially present with non-
muscle-invasive (pTa or pT1) disease that can often be
treated with conservative approaches, however, many pa-
tients suffer from recurrence, occasionally with grade
and/or stage progression. In contrast, for patients with
muscle-invasive bladder cancer the gold standard treat-
ment is radical cystectomy. Radical cystectomy is also
occasionally performed in patients with stage Ta-1 or Tis
tumors that are resistant to intravesical instillation ther-
apy [2]. Though radical cystectomy has some therapeutic
benefits, it is a potentially invasive surgery which re-
quires urinary diversion. Thus, a new marker to predict
the prognosis is needed to determine whether patients
should receive radical cystectomy.
Previous reports have indicated a variety of tissue- or
urine-based biomarkers that can be used for predicting
the recurrence and progression of bladder cancer; these
have often been PCR- or immunohistochemistry-based
* Correspondence: hu0428@yokohama-cu.ac.jp
1Department of Urology, Graduate School of Medicine, Yokohama City
University, Yokohama, Japan
2Departments of Urology and Renal Transportation, Yokohama City
University Medical Center, Yokohama, Japan
Full list of author information is available at the end of the article
© 2016 Kawahara et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kawahara et al. BMC Cancer  (2016) 16:185 
DOI 10.1186/s12885-016-2219-z
methods [3]. A simple, inexpensive and highly accurate
method would be preferable for daily clinical use. The
neutrophil-to-lymphocyte ratio (NLR), which can be eas-
ily calculated from routine complete blood counts
(CBCs) in peripheral blood samples has been suggested
as a predictor, not only for the systemic inflammatory
response in critical care patients [4] but also for the
prognosis of some solid malignancies including bladder
cancer [2, 5–13]. Additionally, the NLR can be obtained
retrospectively even in the postoperative follow-up be-
cause CBCs are routinely examined in various stages of
bladder cancer therapy. In the current study, we assessed
the utility of the NLR in the prediction of the prognosis




A total of 74 patients underwent radical cystectomy for
bladder cancer in Yokohama City University Hospital
(Yokohama, Japan) from February 1999 to April 2014.
All patients were Japanese. Written informed consent
was obtained from each patient, and the institutional re-
view board of the hospital approved this study. The pa-
tients were followed up every three months for two
years postoeratively and then every 6 months thereafter
by either cystoscopy or CT.
Clinical and laboratory assessments
The NLR was calculated using neutrophil and lympho-
cyte counts via CBCs that were obtained a few days be-
fore surgery. CBCs include the number of blood cells,
platelets, and white blood cells with differentiation.
Other variables, including C-reactive protein (CRP) and
lactate dehydrogenase (LDH), were simultaneously ob-
tained. We determined the cut-off points of the NLR,
CRP, and LDH, based on the sensitivity and specificity
levels derived from area under receiver operator charac-
teristics (AUROC) curves plotted for disease progression
or death. None of the patients demonstrated either sys-
temic inflammation or blood disease at the time of the
blood examinations.
Immunohistochemistry
A bladder cancer tissue microarray (TMA) was obtained
from US Biomax (Rockville, MD, USA). The prognostic
data were unavailable for these cases. Immunohisto-
chemical staining was performed for both CD66b and
CD8 to detect tumor infiltrating neutrophils and lym-
phocytes, respectively. An immunohistochemical analysis
was performed, as described previously, using a primary
antibody to CD66b (clone G10F5, diluted at 1:200, BD
Biosciences, San Jose, CA, USA) or CD8 (clone C8/
144B, diluted at 1:100, DAKO Corporation, Carpenteria,
CA, USA) [14]. The slides were then examined by a sin-
gle pathologist (HM) blinded to the sample identity. The
total number of CD68-positive or CD8-positive cells was
counted in each TMA core.
Statistical analysis
The patients’ characteristics and preoperative factors
were analyzed by Mann–Whitney U and chi-square
tests. Multivariate logistic regression models were used
for detecting the individual factors. The Kaplan-Meier
product limit estimator was used to estimate
progression-free survival (PFS) and overall survival (OS).
Survival duration was defined as the time between rad-
ical cystectomy and tumor progression or death. The
log-rank test was performed for comparison. A P value
of <0.05 was considered to be statistically significant.
Results
Patients’ characteristics
The median and mean (± SD) ages of the 74 patients
(male, n = 58; female, n = 16) were found to be 65 and
64.1 (±9.7) years at 24.2 and 29.6 (±24.2) months of
follow-up after radical cystectomy, respectively. The time
of diagnosis varied in each patient, however, no differ-
ences were observed regarding when the patients re-
ceived RC. The clinicopathologic data of these patients,
such as the ECOG-performance status, the performance
of neoadjuvant/adjuvant systemic chemotherapy, the
clinical/pathological T stage, the presence of lymph node
metastasis, and the surgical margin, are summarized in
Table 1. There was no correlation between tumor inva-
siveness and various factors, including age, sex, and
tumor size. To exclude any difference in the diagnostic
time, we classified the patients into two groups accord-
ing to the time of diagnosis and no differences were
observed.
The NLR cut-off value
Based on the AUROC curve, the NLR cut-off point was
determined to be 2.38 for both progression and death
(AUROC: 0.544 and 0.633, respectively) [Fig. 1]. There
were no statistically significant differences in the base-
line characteristics of patients with NLRs of <2.38 in
comparison to those with NLRs of ≥2.38. Similarly, the
cut-off values of CRP (0.08) and LDH (158) were set
(data not shown).
The NLR value and patient outcomes
We first performed a univariate analysis to assess the
risk of death after radical cystectomy. The NLR (HR =
4.84, p = 0.007), CRP (HR = 10.06, p = 0.030), and the
presence of pathological lymph node metastasis (HR =
4.73, p = 0.030) were correlated with significantly higher
risks of death (Table 2). In a multivariate analysis, the
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NLR (HR = 4.62, p = 0.030), CRP (HR = 10.80, p = 0.045),
and pathological lymph node metastasis (HR = 12.35, p
= 0.009) were also found to be significantly associated
with OS [Table 2]. A Kaplan-Meier analysis and log-rank
test further revealed that a high NLR was correlated with
a significantly lower rate of OS, in comparison to a low
NLR (p = 0.018; Fig. 2). However, the association be-
tween the NLR and disease progression was not statisti-
cally significant (p = 0.137).
Tumor infiltrating lymphocytes and tumor grade/stage
CD66b-positve cells were only observed in a few cases
(Fig. 3). Therefore, we analyzed the relationship between
the number of tumor infiltrating CD8-positive lympho-
cytes (Fig. 4) and the tumor grade or stage. The number
of CD8-positive lymphocytes was significantly increased
in high-grade (mean ± SD: 29.4 ± 23.5) and muscle-
invasive (23.8 ± 22.4) tumors, in comparison to low-
grade (15.1 ± 17.1; p = 0.001) and non-muscle-invasive
(15.1 ± 17.8; p = 0.012) tumors. The number of CD8-
positive cells did not differ significantly in benign
urothelial tissues (mean ± SD: 21.6 ± 12.7) and urothelial
carcinomas (19.1 ± 20.0) (p = 0.291).
Discussion
There is increasing evidence to show that the presence
of systemic inflammation is correlated with poorer
cancer-specific survival in several solid tumors, such as
colorectal carcinoma [6, 15–20]. Moreover, non-
steroidal anti-inflammatory medications have been sug-
gested to reduce the risk of developing bladder cancer,
which implies a critical correlation between inflamma-
tion and bladder tumorigenesis [16, 21]. This study re-
vealed systemic inflammation including CRP was an
independent risk factor to estimate the prognosis. The
presence of an inflammatory response can be deter-
mined by both the expression of CRP and an elevation
in the NLR [4, 6, 22]. The latter has indeed been shown
to be associated with a poorer prognosis in patients with
Table 1 Patient characteristics
Total (n = 74) NLR < 2.38 NLR≥ 2.38 p-value
Age
<65 years 32 (43.2 %) 24 (52.9 %) 8 (34.8 %) 0.324
≥65 years 42 (56.8 %) 27 (47.1 %) 15 (65.2 %)
Gender
Female 16 (21.6 %) 11 (21.6 %) 5 (21.7 %) 0.987
Male 58 (78.4 %) 40 (78.4 %) 18 (78.3 %)
ECOG-PS
0 68 (91.9 %) 48 (94.1 %) 20 (87.0 %) 0.270
≥1 6 (8.1 %) 3 (5.9 %) 3 (13.0 %)
Neoadjuvant Chemotherapy
No 64 (86.5 %) 45 (88.2 %) 19 (82.6 %) 0.847
Yes 10 (13.5 %) 6 (11.8 %) 4 (17.4 %)
Clinical T stage
≤2 38 (51.4 %) 26 (51.0 %) 12 (52.2 %) 0.924
≥3 36 (48.6 %) 25 (49.0 %) 11 (47.8 %)
Clinical Lymph Node Metastasis
No 70 (94.6 %) 48 (94.1 %) 22 (95.7 %) 0.633
Yes 4 (5.4 %) 3 (5.9 %) 1 (4.3 %)
Surgical Margin
Negative 68 (91.9 %) 45 (88.2 %) 23 (100.0 %) 0.097
Positive 6 (8.1 %) 6 (11.8 %) 0 (0.0 %)
Adjuvant chemotherapy
No 49 (66.2 %) 35 (68.6 %) 14 (60.9 %) 0.514
Yes 25 (33.8 %) 16 (31.4 %) 9 (39.1 %)
Pathological T stage
≤2 53 (71.6 %) 37 (72.5 %) 16 (69.6 %) 0.792
≥3 21 (28.4 %) 14 (27.5 %) 7 (30.4 %)
Pathological Lymph Node Metastasis
No 64 (86.5 %) 43 (84.3 %) 21 (91.3 %) 0.339
Yes 10 (13.5 %) 8 (15.7 %) 2 (8.7 %)











Fig. 1 Value of the area under the receiver operating characteristics (AUROC) curve
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Table 2 Univariate and multivariate analyses of factors for the OS
Median OS Univariate analysis Multivariate analysis
n (mean ± SD) HR 95%CI p-value HR 95%CI p-value
Age
<65 years 32 2122 (2221.6 ± 1725.5) 1 0.50-4.73 0.453
≥65 years 42 718 (1071.4 ± 1003.6) 1.54
Gender
Female 16 767 (1891.9 ± 1536.9) 1 0.50-12.02 0.272
Male 58 980 (1479.6 ± 13743.5) 2.44
ECOG-PS
0 68 1286 (1673.7 ± 1413.1) 1 0.7021.22 0.121
≥1 6 302 (379.3 ± 319.4) 3.86
NLR
<2.38 51 1250.5 (1576.6 ± 1375.0) 1 1.54-15.23 0.007 1 1.16-18.34 0.030
≥2.38 23 797.5 (1551.3 ± 1487.5) 4.84 4.62
CPR
<0.08 23 1427 (1461.3 ± 1091.4) 1 1.24-81.27 0.030 1 1.06-110.29 0.045
≥0.08 51 772 (1617.2 ± 1533.2) 10.06 10.8
LDH
<158 20 1286 (1464.7 ± 1205.3) 1 0.36-4.47 0.712
≥158 54 808 (1607.3 ± 1565.7) 1.27
Neoadjuvant Chemotherapy
No 64 1244 (1535.9 ± 1339.8) 1 0.15-4.10 0.772
Yes 10 331 (1779.3 ± 2228.4) 0.78
Clinical T stage
≤2 38 980 (1828.6 ± 1722.9) 1 0.39-3.47 0.781
≥3 36 818 (1294.5 ± 1114.1) 1.67
Clinical Lymph Node Metastasis
No 70 818 (1566.6 ± 1492.3) 1 0.11-11.57 0.921
Yes 4 1671 (1607.3 ± 615.3) 1.13
Sugical Margin
Negative 68 11271.5 (1616.1 ± 1431.6) 1 0.85-7.74 0.095
Positive 6 707 (1287.8 ± 2064.0) 2.56
Adjuvant chemotherapy
No 49 722 (1189.7 ± 1200.8) 1 0.48-4.52 0.493
Yes 25 2154 (2311.7 ± 1624.5) 1.48
Pathological T stage
≤2 53 1112 (1586.9 ± 1466.4) 1 0.32-3.52 0.914
≥3 21 982 (1437.4 ± 1603.1) 1.07
Pathological Lymph Node Metastasis
No 64 1244 (1609.8 ± 1466.4) 1 1.17-19.17 0.030 1 1.85-82.47 0.009
Yes 10 718 (1305.9 ± 1523.6) 4.73 12.35
OS: overall survival, ECOG-PS: Eastern Cooperative Oncology Group performance status, NLR: neutrophil-to-lymphocyte ration
CPR: C-reactive protein, LHD: lactate dehydrogenase
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some solid tumors [4, 6, 11, 23, 24]. The proposed mecha-
nisms include increasing the supply of growth factors, sur-
vival factors, pro-antigenic factors, extracellular matrix-
modifying enzymes that can facilitate invasion and metasta-
sis, and inductive signals that may lead to epithelial-to-
mesenchymal transition [25, 26].. The interaction between
the tumor and the immune system of the host not only
promotes tumor cell proliferation and metastasis but also
activates the inflammatory cascade in the host, which leads
to the further deterioration of the general condition of can-
cer patients [27]. The NLR, as an independent parameter,
has been shown to be significantly correlated with serum
CRP levels [28]. However, another study [2], found that the
NLR was not a powerful predictor of survival. Thus, there
is a biological rationale for using the NLR, as a measure of
systemic host response when evaluating the association be-
tween inflammation and cancer outcomes [26].
It has been proposed that the NLR can be used to esti-
mate the magnitude of systemic inflammation in cancer pa-
tients [5, 29–31]. It can easily be calculated from routine
CBCs with differentials [26]. CBCs are usually determined
in the clinical check-ups, thus it is possible to apply the
NLR to all patients, both preoperatively and postopera-
tively. Thus, the NLR is a useful tool when considering add-
itional therapy after radical cystectomy. We also attempted
to investigate the numbers of CD66b-positive neutrophils
and CD8-positive lymphocytes in separate sets of bladder
cancer tissues. An immunohistochemical analysis showed
that CD8-positive cells were present in the majority of
cases, whereas CD66b-positve cells were seen only in a few
cases. Higher numbers of CD8-positive lymphocytes were
strongly correlated with a higher tumor grade or stage. In a
previous immunohistochemical study involving 56 cystec-
tomy cases, a high CD8 density (defined as the presence of
≥60 intra-tumoral CD8-positive cells per high-power field)
was observed in 10 of 45 (22 %) muscle-invasive tumors,
while it was not observed in any of 11 non-muscle-invasive
tumors [32]. In contrast, although all of the cystectomy
cases in which the NLR was assessed in the present study
exhibited muscle-invasive tumors, we found no significant
difference in the NLRs of patients with different pT or pN
stages. Thus, there appeared to be no strong correlation be-
tween the number of CD8-positive lymphocytes in the tis-
sue specimens and the NLR in blood in bladder cancer
patients. Nevertheless, in a previous study using tissue
specimens, a high CD8 density was only associated with a
favorable prognosis in ≥ pT1 tumors, which supports the
prognostic significance of the NLR via CBCs [32].
The present study showed that the NLR was an inde-
pendent prognostic factor in bladder cancer patients
who underwent radical cystectomy. Tumor characteris-
tics are known to assist in the prediction of the risk of
disease recurrence and progression [33]. The European
Organization for Research and Treatment of Cancer
(EORTC) risk table has been commonly used to predict
progression [33–36]. In order to further improve the
prediction, new biomarkers are needed. In bladder can-
cer, several studies have shown the NLR to be a prog-
nostic factor [2, 26, 28, 37–39]. On the other hand, the
association between the NLR and tumor progression re-
mains controversial (Table 3). These studies showed that
a higher NLR was correlated with a worse prognosis in
patients with bladder cancer, while others indicated that





















Fig. 2 Progression-free and overall survivals according to the NLR
Fig. 3 Immunohistochemistry of CD66b in the bladder TMA.
Occasional CD66b-positive neutrophils (arrowheads) are seen in the
stromal tissue. Original magnification, x400
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[2, 26, 28, 37, 38]. In patients with non-muscle-invasive
bladder cancer, an NLR of >2.41 tended to be correlated
with recurrence and progression after transurethral re-
section of bladder tumors [33]. In the present study, a
high NLR was found to be a risk factor for death in pa-
tients with invasive bladder cancer who underwent rad-
ical cystectomy.
The AUROC determined the cut-off value of the NLR
to be 2.38 in the present study. Kayner et al. reported
that MIBC showed a higher NLR compared with
NMIBC, and the cut-off point was set as 2.50 in their
study [40]. Several studies in advanced pancreatic cancer
showed NLR cut-off values of approximately 5 [5]. In
intrahepatic cholangiocarcinoma [6], and in patients
with liver metastasis from colorectal carcinoma [25], the
NLR cut-off value was also set as 5. In urologic cancers,
NLR cut-off values of approximately 5 (prostate cancer)
or from 2 to 5 (renal cell carcinoma) have been used
[41]. In urothelial carcinoma, NLR cut-off values of
2.41-3.0 have been reported [2, 26, 37, 38, 40, 42]. Our
cut-off point for the NLR was thus somewhat lower than
the values of previous reports.
The present study is associated with several limitations.
First, this is a retrospective study, which may have led
Fig. 4 Immunohistochemistry of CD8 in the bladder TMA. Infiltrating CD8-positive lymphocytes are present mainly in the stromal (a, original magnification
x100; b, original magnification x200) or intratumoral (c, original magnification x100; d, original magnification x200) compartments
Table 3 The association between the NLR and the prognosis of urothelial carcinoma
Study Year Number of patients Cut-off value Prognosis (high vs low NLR) Hazard ratio (low NLR was set as 1)
Bladder
Gondo et al. [28] 2012 189 2.5 not mentioned (OS) 1.946, p==0.0015
Demirtas et al. [2] 2013 201 2.5 no significant differences N/A
Krane et al. [37] 2013 68 2.5 23 vs 36 months (CSS) 2.25
Hermanns et al. [26] 2014 424 3 43 % vs 64 % (OS) 1.67, p < 0.001
Temraz et al. [38] 2014 68 2.87 2.7 vs 6.0 years (OS) 1.88
Mano et al. [33] 2014 107 (NMIBC) 2.41 3.74, p = 0.004
Viers et al. [39] 2014 unknown unknown 1.03, p = 0.01
Kayner et al. [40] 2014 291 2.50 NMIBC vs MIBC p = 0.028
Current study 2014 74 2.38 52.6 vs 51.7 months (OS) 4.84, p = 0.007
Upper urinary tract
Azuma et al. [41] 2013 137 2.5 29.4 % vs 81.3 % (OS) 6.14, p < 0.0001
Dalpiaz et al. [9] 2013 202 2.7 27 vs 44.5 months (OS) 3.073, p < 0.001
NLR: neutrophil-to-lymphocyte ration, NMIBC: non-muscle-invasive bladder cancer, MIBC: muscle-invasive bladder cancer, OS: overall survival, CSS:
cancer-specific survival
Kawahara et al. BMC Cancer  (2016) 16:185 Page 6 of 8
selection bias. Second, we did not perform mechanistic ex-
periments to determine the roles of neutrophils and/or
lymphocytes in bladder cancer progression. Nonetheless,
the current results support the findings of previous studies
which indicate correlations between NLR/inflammation
and the clinical outcome of patients with muscle-invasive
bladder cancer. The NLR may thus be useful in the predic-
tion of prognosis in bladder cancer patients after radical
cystectomy.
Conclusions
The current study demonstrated the usefulness of the
NLR in the prediction of OS in patients with advanced
stage bladder cancer. The NLR was thus found to be an
independent prognostic marker for predicting the prog-
nosis. The preoperative NLR predicted prognosis in pa-
tients who underwent radical cystectomy and might
therefore function as a reliable biomarker for invasive
bladder cancer.
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